Skip to main content
2026 Prospectus
National Congenital Cytomegalovirus Awareness Month 2026 executive observance hero.

· Executive Brief

National Congenital Cytomegalovirus Awareness Month 2026

Move from recognition activity to a visible operating route with named owners and closed loops.

Greg Wahlstrom in his office at The Healthcare Executive
Written byMBAHCMPresident and Chief Executive Officer, The Healthcare ExecutiveOctober 2026 30 min read

Leadership signal

Use National Congenital Cytomegalovirus Awareness Month to examine the system behind the message.

Leaders can use this window to test whether public information, service entry points, internal referrals, and follow-up responsibilities form one understandable route. The review should start with the experience of people using the system and the teams responsible for receiving them.

Start by distinguishing what is known from what the organization still needs to learn. A campaign plan, communication volume, or meeting count does not establish that a route is usable. Leaders need direct listening, clear ownership, locally defined measures, and a method for keeping exceptions visible.

Executive opening

Congenital CMV is a detection and follow-through problem

Congenital cytomegalovirus is the most common congenital infection and a leading nongenetic cause of sensorineural hearing loss in children.[2] Most affected newborns look well at birth, which means a health system finds them only if it deliberately looks. National Congenital Cytomegalovirus Awareness Month is a useful moment for leaders to ask whether their organization looks, and what happens after a positive result.

The answer varies widely. Despite expanding legislative screening requirements across the United States, there is no consensus guidance on the screening approach, and implementation varies.[2] Some systems test only newborns who fail hearing screening, some test all newborns in intensive care, and some states now screen every newborn using dried blood spots. Each approach creates different laboratory, nursing, audiology and family communication workloads.

Detection is only the first handoff. In New York’s first year of universal dried blood spot screening, 62 of 529 referred newborns (11.7%) were lost to follow-up or their parents declined follow-up.[1] A large Ohio hospital system that expanded screening found that audiology follow-up was limited by logistical, socioeconomic and educational barriers facing families.[2] Screening without a reliable route to audiology and early intervention creates worry without benefit.

Awareness among the public and clinicians is also low. In a national sample of postpartum women in Greece, only 20% had received information about congenital CMV from their obstetrician during antenatal care.[11] Families in a United Kingdom consultation described diagnostic delays that included health professionals’ lack of awareness.[14]

The sections below summarize current peer-reviewed evidence on burden, screening approaches, laboratory workflows, audiology follow-up, education, equity and measurement. They sit beside the executive guidance already on this page to give boards and operating leaders a shared factual base for deciding where to act first.

Current evidence

What the research says about burden and missed cases

Universal screening studies show how many infections other approaches miss. A prospective program in two Jerusalem hospitals screened 48,556 infants, 94.7% of all live newborns, using pooled saliva testing.[4] It identified congenital CMV in 176 newborns, a birth prevalence of 3.6 per 1000.[4] Of those 176 infants, 100 (57%) would have been missed by an expanded-targeted screening strategy.[4]

A Slovenian national pilot found a similar gap. Among 5556 newborns screened with dried blood spots, cCMV was confirmed in 10, a lower-bound birth prevalence of 1.80 per 1000 live births.[5] None of the confirmed cases were clinically suspected at birth, and all passed newborn hearing screening.[5] Historical clinical case ascertainment in Slovenia corresponded to only 0.09 detected cases per 1000 live births.[5]

Routine practice in the United States has detected far fewer cases. In administrative claims for commercially insured infants from 2007 to 2024, the overall administrative birth prevalence was 3.4 per 10,000 live births.[9] Diagnoses rose from 3.8 to 8.4 per 10,000 live births between 2021 and 2024.[9] In neonatal intensive care units, only 10,033 of 840,988 admitted newborns (1.2%) were tested from 2010 to 2020.[10]

Missed cases matter because hearing loss can appear later. A meta-analysis of three prospective universal screening studies covering 56,892 newborns found that 83.4% of infected infants were asymptomatic.[13] Late hearing impairment occurred in a pooled proportion of 13.9%, and one study reported long-term neurological sequelae in 11% of asymptomatic patients.[13] In Connecticut, among children with hearing loss at birth, hearing worsened in 81%, and only 21% of children with follow-up remained without sequelae.[3]

Testing patterns are shifting even without universal screening. Among NICU newborns who were tested, the proportion with one or fewer clinical signs rose from 12.9% to 32.0% between 2010 and 2020.[10] Of the 10,033 tested newborns, 559 (5.6%) were diagnosed with cCMV infection.[10] Clinicians are casting a wider net, but testing still depends on individual judgment unless a system makes it routine. For executives, the pattern is consistent across settings. Targeted approaches find some infants, universal approaches find more, and every approach depends on a follow-up system that can absorb the new caseload. The question for leaders is not whether cases exist in their population, but whether their current approach can see them and what the organization will do once it does.

Figure 1

Testing and follow-through gaps across congenital CMV pathways

Testing and follow-through gaps across congenital CMV pathwaysPercent of each study's reported denominator, as stated in each abstract. Values are copied from the cited studies [1], [4], [7], [9], [10]; none is estimated.0%25%50%75%100%NICU newborns tested for cCMVNICU newborns tested for cCMV: 1.2% (source [10])1.2%[10]Referred hearing-screen infants testedbefore reflex policyReferred hearing-screen infants tested before reflex policy: 7.7% (source [7])7.7%[7]Referred hearing-screen infants testedafter reflex policyReferred hearing-screen infants tested after reflex policy: 95.2% (source [7])95.2%[7]Infected infants that expanded-targetedscreening would missInfected infants that expanded-targeted screening would miss: 57% (source [4])57%[4]Diagnosed infants prescribed antiviraltreatmentDiagnosed infants prescribed antiviral treatment: 18.4% (source [9])18.4%[9]Screen-positive newborns lost to ordeclining follow-upScreen-positive newborns lost to or declining follow-up: 11.7% (source [1])11.7%[1]Source [10]Source [7]Source [4]Source [9]Source [1]Shade and hatching group bars by study; the studies differ in population and setting, so bars compare only within a shade

Percent of each study’s reported denominator, as stated in each abstract. Values are copied from the cited studies [1], [4], [7], [9], [10]; none is estimated.

Data note. These values come from different studies, countries, years and denominators, so this is an indirect comparison; only the two bars from the same center describe a before-and-after change.

Limitation. Each value reflects its own setting and definition; the antiviral figure covers commercially insured infants only, and the before-and-after values come from one center.

Figure data (6 rows)
Figure 1 data: Testing and follow-through gaps across congenital CMV pathways
MeasureValuePopulation, setting and year as reportedSource
NICU newborns tested for cCMV1.2%10,033 of 840,988 newborns admitted to 389 U.S. NICUs in 35 states, 2010 to 2020[10]
Referred hearing-screen infants tested before reflex policy7.7%High-volume center, before a provider education program and automated nursing order[7]
Referred hearing-screen infants tested after reflex policy95.2%Same center after implementation; 91079 infants included from 2016 to 2023[7]
Infected infants that expanded-targeted screening would miss57%100 of 176 infants identified by universal pooled saliva screening, two Jerusalem hospitals, 2022 to 2025[4]
Diagnosed infants prescribed antiviral treatment18.4%Commercially insured U.S. infants with diagnosed cCMV, 2007 to 2024[9]
Screen-positive newborns lost to or declining follow-up11.7%62 of 529 referred newborns, New York State universal screening, October 2023 to September 2024[1]
A nurse-midwife talks with a pregnant woman about hand hygiene around toddlers as her preschooler colors nearby.
Illustrative image. Universal screening in two Jerusalem hospitals found that 57% of infected infants would have been missed by expanded-targeted screening.[4]

Continuum of care

From positive screen to audiology, specialty care and early intervention

A positive screen starts a chain of handoffs. In New York, infectious disease specialists at designated medical centers performed follow-up of referred newborns.[1] Of 529 newborns with positive screens, 276 (52.2%) were diagnosed with congenital CMV after initial evaluation, and 131 (24.8%) had likely acquired CMV after birth.[1] Among the 68 newborns with symptomatic disease, 48 (70.6%) were treated with antiviral medication.[1] Each of those steps depends on referral, scheduling and result communication working on time.

Timing is the hardest part of the route. In a Danish region, testing of infants who failed hearing screening rose to 113 (90%) by the second year of a targeted program.[15] Even so, no children with CMV-related hearing loss were diagnosed in time to initiate treatment.[15] Nine of 11 positive saliva samples were not confirmed infections, a high share of unconfirmed positives in a small program.[15] A targeted program can be implemented and still miss its purpose if the interval from hearing screen to confirmed diagnosis is too long. Leaders should measure that interval directly.

Audiology and early intervention are where the long-term value appears. A Utah health system’s expanded targeted program detected 32 confirmed cases over 3.5 years.[8] Hearing loss was found in 9 of 32 children (28%); 5 were fitted with hearing aids, and 3 received bilateral cochlear implants at a median age of 11 months.[8] Those outcomes required audiology, otolaryngology and surgical services to receive each referral and keep children on schedule.

Follow-up must continue well beyond the newborn period. Because late hearing impairment appears in a meaningful share of asymptomatic infants, the meta-analysis authors warned that the absence of structured screening risks missing these patients in long-term follow-up.[13] In Connecticut, 75% of children who were asymptomatic or had isolated hearing loss after the mandate later developed neurodevelopmental sequelae.[3] Leaders should treat repeat audiology and developmental review as a scheduled pathway with owners, not a reminder in a discharge summary.

Treatment practice is also shifting. Among commercially insured infants with diagnosed cCMV, 18.4% were prescribed antiviral treatment, and the proportion increased with the number and severity of signs at birth.[9] The authors called for research on outcomes in asymptomatic infants as systematic screening detects more of them.[9]

Figure 3

Why the pathway breaks

Cause-and-effect diagram: Infants with congenital CMV are not detected in time or do not complete audiology and early intervention follow-upUnranked qualitative cause-and-effect diagram for the outcome in the box: Infants with congenital CMV are not detected in time or do not complete audiology and early intervention follow-up Causes are assembled from the cited literature [1], [2], [3], [6], [7], [9], [11], [14]; categories are not weighted and their order carries no meaning.Infants with congenital CMVare not detected in time or donot complete audiology andearly intervention follow-upPeopleProcessTechnologyEnvironmentPolicyMeasurement

People

  • Clinicians unaware of congenital CMV
  • Few prenatal counseling conversations
  • Audiology and coordinator capacity not matched to screening volume

Process

  • Testing after failed hearing screen depends on individual orders
  • No owner from positive screen to audiology
  • Confirmatory testing delayed past the newborn window

Technology

  • Specimen choice with lower sensitivity or false positives
  • Results not routed to the receiving clinician
  • No shared tracking of follow-up completion

Environment

  • Transportation and work barriers for families
  • Distance to pediatric audiology
  • Low community awareness of transmission

Policy

  • No consensus guidance on screening approach
  • State mandates that vary in scope
  • Coverage limits for follow-up services

Measurement

  • Coverage reported without follow-up completion
  • Claims data that understate prevalence
  • Results not stratified by payer or language

Unranked qualitative cause-and-effect diagram for the outcome in the box: Infants with congenital CMV are not detected in time or do not complete audiology and early intervention follow-up Causes are assembled from the cited literature [1], [2], [3], [6], [7], [9], [11], [14]; categories are not weighted and their order carries no meaning.

Data note. Qualitative; no frequencies are implied.

Limitation. Causes drawn from published studies may not all apply locally; validate them with frontline teams.

Figure data (6 rows)
Figure 3 data: Why the pathway breaks
CategoryCauses drawn from the cited literature
PeopleClinicians unaware of congenital CMV; Few prenatal counseling conversations; Audiology and coordinator capacity not matched to screening volume
ProcessTesting after failed hearing screen depends on individual orders; No owner from positive screen to audiology; Confirmatory testing delayed past the newborn window
TechnologySpecimen choice with lower sensitivity or false positives; Results not routed to the receiving clinician; No shared tracking of follow-up completion
EnvironmentTransportation and work barriers for families; Distance to pediatric audiology; Low community awareness of transmission
PolicyNo consensus guidance on screening approach; State mandates that vary in scope; Coverage limits for follow-up services
MeasurementCoverage reported without follow-up completion; Claims data that understate prevalence; Results not stratified by payer or language

Access

Screening approach, laboratory workflow and the cost of each choice

The choice of specimen shapes the laboratory route. A meta-analysis of 19 studies with 103,669 neonates found pooled sensitivity of 0.95 for saliva PCR and 0.72 for dried blood spot PCR.[6] Both methods showed high specificity, at 1.00 for saliva and 0.99 for dried blood spots.[6] The authors supported saliva PCR where feasible and dried blood spot PCR as a complementary option in large-scale or resource-limited settings.[6]

Dried blood spots fit existing newborn screening infrastructure. New York reported screening results for 208,099 newborns over one year, and 529 (0.3%) had positive screens.[1] Slovenia showed that universal dried blood spot screening is feasible within an established national newborn screening program.[5] Pooled saliva testing offered another route in Jerusalem, with a pooling efficiency of 5.82 samples per single test.[4] That approach carried a 3.7 cycle threshold loss of sensitivity, and the authors noted that further cost-benefit analyses are needed.[4]

Targeted approaches change workflow inside the hospital. Connecticut mandated testing for newborns who fail hearing screening in 2016.[3] Within a health system serving about 60% of the state’s population, the mandate was associated with a 4.32-fold increase in annual diagnoses.[3] Before the mandate, no cases were asymptomatic; afterward, 28% were asymptomatic or had isolated hearing loss.[3] The authors concluded that many infections likely remain undetected and that universal screening deserves consideration.[3]

Hybrid models are also workable at scale. A large Ohio hospital system used universal screening in neonatal intensive care units and targeted screening in newborn nurseries.[2] Among 50,438 live births, 7491 infants (14.9%) were screened from 2022 to 2025, and annual testing grew from about 150 to over 2000 infants.[2] Detection increased approximately 2.5-fold, with 34 infants (0.45%) confirmed.[2] Whichever model a system chooses, specimen collection, courier, laboratory capacity and result routing must be designed together.

Each model also carries its own cost and staffing profile. Universal dried blood spot screening relies on a state newborn screening laboratory and a network of designated follow-up centers, as in New York.[1] Ohio’s hospital-based hybrid model instead relied on a multidisciplinary clinical and laboratory team, and audiology follow-up became its weak point.[2] Executives should know which model their state uses, what share of the work falls on their own organization and where capacity must grow.

Executive guidance · System route

Connect the month to an accountable system route.

Use this route as a discussion framework. Replace each stage with the organization’s approved process, qualified roles, current service capacity, and applicable requirements. Do not infer a clinical protocol from the observance title.

The route at a glance

  1. Listen
  2. Clarify entry
  3. Coordinate the partner route
  4. Protect transitions
  5. Verify and learn

Reliability rule: Every stage needs a named owner, an observable status, an approved escalation path, and a defined signal that shows whether responsibility moved or remained unresolved.

  1. Listen

    Gather questions and friction points from people using the route, frontline teams, and community-facing staff. Separate observed barriers from assumptions.

  2. Clarify entry

    Publish a plain-language first step and identify who receives requests through each approved channel.

  3. Coordinate the partner route

    Align internal teams and external partners around one current message, real entry point, receiving owner, escalation path, and follow-through signal.

  4. Protect transitions

    Use acknowledgment and status visibility when responsibility moves between services, locations, or organizations.

  5. Verify and learn

    Review unresolved work, repeat contacts, and avoidable handoffs. Use the findings to improve the route rather than blame individuals.

Figure 2

The system route as one flow

The system route as one flowThe five stages of the system route described in this brief, drawn as one flow with a learning loop back to the start. The stages are the page’s original executive guidance, not a clinical protocol.ListenClarify entryCoordinate thepartner routeProtecttransitionsVerify and learnLearning returns to the start of the route

The five stages of the system route described in this brief, drawn as one flow with a learning loop back to the start. The stages are the page’s original executive guidance, not a clinical protocol.

Data note. Shows sequence and handoffs only; it carries no counts or rates.

Limitation. Local processes may add, merge or reorder stages under organizational policy.

Figure data (5 rows)
Figure 2 data: The system route as one flow
StageWhat the stage requires
ListenGather questions and friction points from people using the route, frontline teams, and community-facing staff. Separate observed barriers from assumptions.
Clarify entryPublish a plain-language first step and identify who receives requests through each approved channel.
Coordinate the partner routeAlign internal teams and external partners around one current message, real entry point, receiving owner, escalation path, and follow-through signal.
Protect transitionsUse acknowledgment and status visibility when responsibility moves between services, locations, or organizations.
Verify and learnReview unresolved work, repeat contacts, and avoidable handoffs. Use the findings to improve the route rather than blame individuals.

Equity and trust

Equity, awareness and family trust

Follow-up gaps fall hardest on families with the fewest resources. The Ohio system reported that audiology follow-up was limited by logistical, socioeconomic and educational barriers.[2] Transportation, work schedules, insurance and language can turn a single missed audiology visit into a lost diagnosis. Leaders can stratify follow-up completion by payer, preferred language and distance to see where the route is failing.

Awareness is uneven and tracks education. In the Greek national study of 467 postpartum women, 43% had heard about congenital CMV, and 57.6% were unaware of transmission routes.[11] Awareness was associated with older age, higher education, a healthcare occupation and antenatal screening.[11] When awareness depends on education or occupation, prenatal counseling becomes an equity tool rather than an optional extra. Programs that rely on families to seek information on their own will widen these gaps.

Brief education can shift attitudes quickly. Among 589 women surveyed in Jordan, only 16.3% had heard of CMV.[12] After receiving educational information, 91.7% believed screening should be offered to pregnant women and 94.9% to newborns.[12] In addition, 71.3% said they would choose prenatal screening in a future pregnancy.[12] These findings suggest that families support screening once someone explains it.

Trust also depends on choice and transparency. In New York, parents could opt out of receiving CMV results, and 245 newborns (0.1%) were opted out.[1] Twenty-two families opted out after results were released.[1] A low opt-out rate is encouraging, but the families who decline or disappear from follow-up deserve outreach that respects their decision and explains what the result means.

Families who were not screened describe lasting harm. In the United Kingdom consultation, respondents described a sense of injustice and unfairness tied to possible missed opportunities to improve outcomes.[14] They viewed newborn screening as a way to avoid delays in diagnostic pathways.[14] Their experience is a reminder that missed detection is felt as a question of fairness, not only a clinical one. Equity also means looking at each entry point separately. In the Ohio hybrid model, detection rates were higher in the targeted nursery group than in the universal intensive care group, at 0.74% versus 0.33%.[2] Different entry points can produce different yields. Leaders should check whether any newborn population, such as infants born at smaller community hospitals or transferred after birth, falls outside every screening rule.

A medical lab scientist logs a newborn saliva sample into an analyzer in a hospital laboratory.
Illustrative image. Audiology follow-up after screening was limited by logistical, socioeconomic and educational barriers in one large hospital system.[2]

Human infrastructure

The teams that make a CMV program work

Congenital CMV programs cross many professional boundaries. The Ohio system built its program through a multidisciplinary team representing key clinical and laboratory specialties.[2] The authors concluded that multidisciplinary collaboration is essential to successful implementation.[2] Nursery nurses, laboratory staff, neonatologists, infectious disease clinicians, audiologists, otolaryngologists and care coordinators all hold a piece of the route.

Standard work can replace memory. A high-volume center introduced a provider education program and a policy automating a nursing order for CMV testing before discharge after a referred newborn hearing screen.[7] Among 91079 infants from 2016 to 2023, the share of referred infants who received CMV screening rose from 7.7% to 95.2%.[7] The authors supported standardized hospital protocols and education to implement state mandates.[7]

Clinician awareness is a workforce issue as well as a public one. In the Greek national study, only 20% of women had received information about congenital CMV from their obstetrician, and antenatal counseling was associated with greater awareness.[11] In the United Kingdom consultation, many families described delays in diagnosis that included health professionals’ lack of awareness of the infection.[14] Obstetric, pediatric and primary care teams need simple scripts and referral rules.

Specimen choice affects staff time. In Denmark, saliva and urine samples were collected from the same number of infants, and nine of 11 positive saliva samples were not confirmed infections.[15] The authors concluded that urine samples seemed preferable for targeted screening in their setting.[15] Every false-positive result adds a confirmatory test, a call to the family and a follow-up visit, so laboratory and nursing leaders should review specimen performance together.

Follow-up capacity must match detection. When annual testing grew from about 150 to over 2000 infants in Ohio, the authors concluded that better access to audiology and other follow-up care was needed.[2] Leaders should size audiology slots, coordinator caseloads and early intervention referrals before screening expands rather than after. Specialty follow-up depends on a small number of clinicians. In New York, follow-up of referred newborns was concentrated at designated medical centers with infectious disease specialists.[1] In Utah, some children with hearing loss received bilateral cochlear implants at a median age of 11 months.[8] Recruiting and retaining pediatric audiologists, otolaryngologists and coordinators is therefore part of any CMV screening decision, not a separate workforce question for later.

Executive guidance · Operating dashboard

Review reliability, not campaign activity alone.

Do not publish a number until the organization defines its numerator, denominator where relevant, owner, source system, exclusions, review cadence, and limits. The candidates below are management prompts, not benchmarks or reported results.

Four operating signals

Entry-point clarityOwnership reliabilityPartner-route reliabilityImprovement closure

Each signal pairs an executive question with one candidate local measure, set out below.

Executive guidance · Signal

Entry-point clarity

Can people and staff identify the approved first step without searching across conflicting instructions?

Candidate local measure
Locally defined contact, routing, and repeat-contact signals by channel and service.

Executive guidance · Signal

Ownership reliability

Does a specific team accept each request and make its status visible?

Candidate local measure
Requests without an owner, aged work, transfers, and escalations using locally approved definitions.

Executive guidance · Signal

Partner-route reliability

Do participating teams share one current route and understand who owns each dependency?

Candidate local measure
Locally defined conflicting instructions, unaccepted handoffs, unresolved dependencies, repeat contacts, and partner feedback.

Executive guidance · Signal

Improvement closure

Does the organization correct recurring friction and report what changed?

Candidate local measure
Selected barriers, assigned actions, completion status, and post-change review.

Figure 4

The operating system behind the dashboard

The operating system behind the dashboardThe four operating signals from this brief’s dashboard, each tied to the candidate owner named in the executive scorecard, around one accountable route. Drawn from the page’s original executive guidance.Accountableoperating route(executive sponsor)Entry-point clarityOwner: Executive sponsor andoperational leadOwnership reliabilityOwner: Operational owner andparticipating teamsPartner-route reliabilityOwner: Sending and receiving ownersImprovement closureOwner: Improvement owner andexecutive sponsor

The four operating signals from this brief’s dashboard, each tied to the candidate owner named in the executive scorecard, around one accountable route. Drawn from the page’s original executive guidance.

Data note. Structural diagram; no measured values.

Limitation. Owners are candidates to be confirmed locally.

Figure data (4 rows)
Figure 4 data: The operating system behind the dashboard
Operating signalCandidate owner
Entry-point clarityExecutive sponsor and operational lead
Ownership reliabilityOperational owner and participating teams
Partner-route reliabilitySending and receiving owners
Improvement closureImprovement owner and executive sponsor

Executive guidance · Handoff workflow

Transfer responsibility with acknowledgment and visibility.

A handoff is reliable only when the sending party knows who is expected to receive the work, the receiving party acknowledges responsibility, and any unresolved exception remains visible. Local policy and qualified judgment control the actual process.

How responsibility moves

Lane AFrom message to accepted ownership4 steps
Lane BFrom accepted ownership to verified follow-through4 steps

Lane A

From message to accepted ownership

  1. Confirm the approved message and intended audience.
  2. Publish the actual entry point and receiving role.
  3. Acknowledge receipt using the locally approved method.
  4. Escalate when ownership or response remains unclear.

Lane B

From accepted ownership to verified follow-through

  1. Record the next accountable owner and visible status.
  2. Name the sending and receiving owners, shared information, current status, and unresolved dependency.
  3. Keep unresolved work visible across boundaries.
  4. Confirm closure or document the continuing exception.

Executive guidance · Executive scorecard

Connect operating signals to accountable executive review.

The scorecard keeps review focused on decisions. Leaders should set definitions locally, examine variation without overclaiming cause, and pair quantitative signals with the experience of people who use and operate the route.

Who reviews what

  • Executive sponsor and operational lead
  • Operational owner and participating teams
  • Sending and receiving owners
  • Improvement owner and executive sponsor

Candidate owners named in the scorecard, confirmed locally.

Candidate questions and ownership assignments. These are not external benchmarks.
Operating signalExecutive questionCandidate ownerSuggested review point
Entry-point clarityCan people and staff identify the approved first step without searching across conflicting instructions?Executive sponsor and operational leadAt campaign launch and close
Ownership reliabilityDoes a specific team accept each request and make its status visible?Operational owner and participating teamsAt a locally defined cadence
Partner-route reliabilityDo participating teams share one current route and understand who owns each dependency?Sending and receiving ownersAt a locally defined cadence
Improvement closureDoes the organization correct recurring friction and report what changed?Improvement owner and executive sponsorUntil action is verified

Figure 5

Control points for a reliable congenital CMV pathway

Figure 5: Control points for a reliable congenital CMV pathway
Control pointRisk if missingOwnerEvidence of control
Prenatal CMV prevention informationFamilies never hear about transmission or screeningObstetrics service line leaderShare of prenatal records with documented CMV education
Automated testing order after a failed hearing screen or per universal policyEligible newborns leave without testingNursery nurse manager and newborn screening leadShare of eligible newborns tested before discharge
Specimen and laboratory workflowLow sensitivity or false positives add delay and repeat testingLaboratory directorTurnaround time and confirmatory testing completion
Positive result routed to a named clinicianResults sit unread and the treatment window passesPediatric infectious disease leadTime from positive screen to family contact and evaluation
Scheduled audiology follow-upLate-onset hearing loss goes undetectedAudiology managerShare of confirmed infants completing scheduled audiology visits
Early intervention referral and confirmationChildren with hearing loss or developmental needs wait for servicesCare coordination leadReferral acceptance confirmed by the receiving program
Board-level reporting with equity stratificationGaps by payer, language or distance stay invisibleChief medical officer and board quality committeeCoverage and follow-up completion reported by subgroup

Control points derived from the cited evidence [1], [2], [6], [7], [11], [13], [15] and this brief’s executive guidance.

Data note. Each row is a control to verify, not a measured result.

Limitation. Owners and evidence of control must follow local policy and applicable requirements.

Public communication

Public communication, measurement and governance

Prevention messages need to reach people before and during pregnancy. In Jordan, childcare-related behaviors that may increase transmission, such as kissing children on the lips or sharing cups and food, were commonly reported.[12] The authors called for comprehensive CMV education and increased public health messaging on transmission.[12] Awareness campaigns can pair hygiene information with a clear explanation of how newborn screening and follow-up work locally.

Measurement should follow the whole route, not just the test. New York reported each outcome category for its 529 referred newborns, including 17 false-positive results (3.2%) and 43 with unknown classification (8.1%).[1] That level of accounting lets leaders see where the route leaks. Systems can track screening coverage, time to confirmatory testing, audiology completion and early intervention referral as one chain.

Data sources shape what leaders see. Claims-based birth prevalence of 3.4 per 10,000 live births is far below the 3.6 per 1000 found through universal screening in Jerusalem.[9][4] Those figures come from different countries, methods and populations, so they cannot be compared directly. Even so, they show that administrative data alone may understate the burden a system is responsible for.

Governance needs a single owner. Congenital CMV screening touches newborn nursery operations, laboratory services, audiology, specialty clinics and community early intervention, and no one department sees the full pathway. Boards should ask which executive owns screening coverage and follow-up completion, and how results are reported alongside other newborn screening measures. Universal screening data could also inform public health guidelines, according to the Jerusalem investigators.[4]

Public communication should be honest about uncertainty. Investigators continue to call for long-term data on outcomes among newborns with asymptomatic infection.[1] Messages for National Congenital Cytomegalovirus Awareness Month can explain what screening is offered, what a positive result means and who will call the family next. They can also report what the organization measured during the month and what it changed as a result. Messages should reach clinicians as well as families. Case conferences, short referral guides and nursery huddles can explain the local screening approach, what a positive result triggers and who owns the next call. Women in the Jordanian study showed strong support for newborn screening after brief education, at 94.9%.[12] Clinician-facing messages that are equally brief and concrete can help staff answer family questions consistently.

An audiologist smiles as a baby on his mother's lap turns toward a soft sound in an audiology booth.
Illustrative image. An automated nursing order paired with clinician education raised testing after referred hearing screens from 7.7% to 95.2% at one center.[7]

Executive guidance · 90-day plan

Use 90 days to correct one visible operating barrier.

The time boxes below are a management framework, not a clinical timeline. Adjust them to risk, scope, governance, resources, stakeholder participation, and applicable review requirements.

Ninety days, three moves

  1. Days 1–30See the current route
  2. Days 31–60Build the reliable path
  3. Days 61–90Make the change visible

Days 1–30 · Listen and map

See the current route

  • Name an executive sponsor and an operational owner.
  • Listen to people using the route and representative frontline teams.
  • Map how National Congenital Cytomegalovirus Awareness Month communications connect to real entry points, owners, transitions, and escalation.
  • Select one recurring barrier that the organization can responsibly address.

Days 31–60 · Design and test

Build the reliable path

  • Define the trigger, receiving owner, required information, acknowledgment, escalation, and closure signal.
  • Validate the design with every sending and receiving team involved.
  • Test one internal or partner handoff and correct a verified communication, dependency, or ownership gap.
  • Test the route in more than one representative setting or operating period where practical.

Days 61–90 · Implement and verify

Make the change visible

  • Launch the redesigned route with a small set of locally defined measures.
  • Review unresolved work and recurring friction using a learning approach.
  • Correct implementation barriers and record who owns each remaining dependency.
  • Report what changed, what evidence was reviewed, and what still requires live oversight.

Figure 6

The 90-day plan on one timeline

The 90-day plan on one timelineThe 90-day plan from this brief drawn as a timeline: each action sits in the 30-day window the plan assigns it. The full wording of each action is in the figure data and in the plan above.Day 0Day 30Day 60Day 90Name an executive sponsor and an operational owner.Days 1–30: Name an executive sponsor and an operational owner.Listen to people using the route and representative frontlineteams.Days 1–30: Listen to people using the route and representative frontline teams.Map how National Congenital Cytomegalovirus Awareness Monthcommunications connect to real entry points, owners,transitions, and escalation.Days 1–30: Map how National Congenital Cytomegalovirus Awareness Month communications connect to real entry points, owners, transitions, and escalation.Select one recurring barrier that the organization canresponsibly address.Days 1–30: Select one recurring barrier that the organization can responsibly address.Define the trigger, receiving owner, required information,acknowledgment, escalation, and closure signal.Days 31–60: Define the trigger, receiving owner, required information, acknowledgment, escalation, and closure signal.Validate the design with every sending and receiving teaminvolved.Days 31–60: Validate the design with every sending and receiving team involved.Test one internal or partner handoff and correct a verifiedcommunication, dependency, or ownership gap.Days 31–60: Test one internal or partner handoff and correct a verified communication, dependency, or ownership gap.Test the route in more than one representative setting oroperating period where practical.Days 31–60: Test the route in more than one representative setting or operating period where practical.Launch the redesigned route with a small set of locallydefined measures.Days 61–90: Launch the redesigned route with a small set of locally defined measures.Review unresolved work and recurring friction using a learningapproach.Days 61–90: Review unresolved work and recurring friction using a learning approach.Correct implementation barriers and record who owns eachremaining dependency.Days 61–90: Correct implementation barriers and record who owns each remaining dependency.Report what changed, what evidence was reviewed, and whatstill requires live oversight.Days 61–90: Report what changed, what evidence was reviewed, and what still requires live oversight.Listen and mapDesign and testImplement and verify

The 90-day plan from this brief drawn as a timeline: each action sits in the 30-day window the plan assigns it. The full wording of each action is in the figure data and in the plan above.

Data note. Time boxes are a management framework, not a clinical timeline.

Limitation. Durations are uniform 30-day windows; real tasks may span windows.

Figure data (12 rows)
Figure 6 data: The 90-day plan on one timeline
WindowAction
Days 1–30 · Listen and mapName an executive sponsor and an operational owner.
Days 1–30 · Listen and mapListen to people using the route and representative frontline teams.
Days 1–30 · Listen and mapMap how National Congenital Cytomegalovirus Awareness Month communications connect to real entry points, owners, transitions, and escalation.
Days 1–30 · Listen and mapSelect one recurring barrier that the organization can responsibly address.
Days 31–60 · Design and testDefine the trigger, receiving owner, required information, acknowledgment, escalation, and closure signal.
Days 31–60 · Design and testValidate the design with every sending and receiving team involved.
Days 31–60 · Design and testTest one internal or partner handoff and correct a verified communication, dependency, or ownership gap.
Days 31–60 · Design and testTest the route in more than one representative setting or operating period where practical.
Days 61–90 · Implement and verifyLaunch the redesigned route with a small set of locally defined measures.
Days 61–90 · Implement and verifyReview unresolved work and recurring friction using a learning approach.
Days 61–90 · Implement and verifyCorrect implementation barriers and record who owns each remaining dependency.
Days 61–90 · Implement and verifyReport what changed, what evidence was reviewed, and what still requires live oversight.

Executive guidance · Leadership close

Pair recognition with a system people can trust.

Recognition matters. It becomes durable when leaders also listen, clarify the route, support the people operating it, close an identified gap, and report the result without claiming more than the evidence supports.

Leadership commitment

Connect the message to one usable, measured, and sustained operating change.

Executive action kit · Month observance

Turn National Congenital Cytomegalovirus Awareness Month into accountable action.

Move from recognition activity to a visible operating route with named owners and closed loops.

Take it with you

Filed under

Public Health and PreventionMonth

Leadership focus

Use this observance to examine trustworthy information, prevention access, and community connection. Select one verified barrier, assign an accountable owner, and carry the improvement beyond the campaign window.

Workforce lens

Ask whether staffing, role clarity, training, tools, workload, and escalation support the people operating the information, access, coordination, and follow-through pathway.

Patient and community lens

Make the approved first step clear. Test whether a person can move from information to an acknowledged next action without navigating conflicting instructions.

Equity and access lens

Review language, disability, transportation, digital access, geography, trust, and other barriers using protected feedback and locally appropriate data.

Five-minute briefing

Inspect the operating sequence

Listen with people using the pathway, frontline teams, operational leaders, and community partners. Find one a message, request, referral, or handoff that does not reach an accountable owner, then test the locally approved route from entry through acknowledged follow-through.

  1. Listen
  2. Clarify entry
  3. Coordinate the partner route
  4. Protect transitions
  5. Verify and learn
Leadership actions for this week
  • Name an executive sponsor and frontline operating owner.
  • Ask people using and operating the pathway where ownership becomes unclear.
  • Test one representative route from first question to acknowledged next step.
  • Select one barrier that can be corrected without overstating the evidence.
  • Set a review date and define how completion will be verified.
Candidate measures

Define every numerator, denominator where relevant, owner, data source, exclusions, cadence, and limitation locally. These are management prompts, not external benchmarks.

  • Locally defined contact, routing, and repeat-contact signals by channel and service.
  • Requests without an owner, aged work, transfers, and escalations using locally approved definitions.
  • Locally defined conflicting instructions, unaccepted handoffs, unresolved dependencies, repeat contacts, and partner feedback.
Department readiness checklist
  • The public and staff entry points match the actual approved process.
  • A specific role accepts each request, referral, or escalation.
  • Handoffs include acknowledgment and a visible unresolved state.
  • Language, disability, digital, transportation, and trust barriers receive explicit review.
  • Communications do not introduce unsupported themes, statistics, or clinical advice.
  • A named leader will review what changed after the observance.
Intended audiences
  • Executive and Operational Leaders
  • Public Health and Community Partners
Staff communication template

During National Congenital Cytomegalovirus Awareness Month, our organization will connect awareness with a practical review of the information, access, coordination, and follow-through pathway. Use approved information, identify the correct entry point, confirm ownership when work moves, protect privacy, and escalate unresolved barriers through local channels.

Community communication template

National Congenital Cytomegalovirus Awareness Month is an opportunity to share trustworthy information and make the next step easier to find. Use our approved channels for information and support. If a request changes hands, our goal is to keep ownership and follow-through visible.

Measurement worksheet
Signal
What observable condition will show whether the route works?
Definition
What is included, excluded, and counted?
Owner
Who reviews the signal and acts on exceptions?
Cadence
When will leaders review it?
Equity check
Which differences require protected, locally appropriate review?
Closure
What evidence will confirm the improvement was completed?
Editorial review
Completed
Source records
2 listed under Authoritative resources
Review standard
Sourced facts remain separated from original executive guidance
Clinical boundary
No new statistical or clinical claim was added by this action kit

Sources and content boundary

Authoritative resources

Use note: All operating models, measures, scorecard questions, and action steps are original executive guidance. This article supports leadership planning and education. It does not replace clinical judgment, emergency procedures, legal advice, professional standards, organizational policy, or applicable federal, state, and local requirements.

Peer-reviewed references

References

Fifteen peer-reviewed sources, newest first. Each was individually verified through authenticated academic research databases. Bracketed numbers in the text link here; the original executive guidance on this page carries no citations because it is guidance, not a sourced claim. Sources last checked in those databases on .

  1. 1. Universal Newborn Screening for Congenital Cytomegalovirus Using Dried Blood Spot Specimens. JAMA Network Open. 2026;9(1):e2554518. https://doi.org/10.1001/jamanetworkopen.2025.54518
  2. 2. Implementing Congenital CMV Screening in a Large Hospital System. Pediatrics. 2026;158(4):e2026076776. https://doi.org/10.1542/peds.2026-076776
  3. 3. Hearing-Targeted Congenital Cytomegalovirus Screening: An 11-Year Experience. Pediatrics. 2026;158(2):e2025074229. https://doi.org/10.1542/peds.2025-074229
  4. 4. Lessons derived from a 3-year congenital cytomegalovirus screening programme in Israel: a prospective population-based cohort study. The Lancet Infectious Diseases. 2026;26(4):384-393. https://doi.org/10.1016/s1473-3099(25)00620-6
  5. 5. Universal Dried Blood Spot Screening for Congenital Cytomegalovirus: A Slovenian National Implementation Pilot. International Journal of Neonatal Screening. 2026;12(3):48. https://doi.org/10.3390/ijns12030048
  6. 6. Comparative diagnostic performance of saliva PCR and dried blood spot PCR for congenital cytomegalovirus detection: a systematic review and meta-analysis. BMC Infectious Diseases. 2026;26(1):1189. https://doi.org/10.1186/s12879-026-13494-1
  7. 7. Evaluation of reflexive, hearing-targeted congenital cytomegalovirus screening at a high-volume center. Journal of Perinatology. 2026. https://doi.org/10.1038/s41372-026-02897-2
  8. 8. Update on an Expanded Targeted Early Cytomegalovirus Testing Program From a Large Health Care System. Otology & Neurotology. 2026;47(3):525-530. https://doi.org/10.1097/mao.0000000000004811
  9. 9. Antiviral Use Among Infants Diagnosed With Congenital Cytomegalovirus (cCMV) in the United States: A Retrospective Analysis of Administrative Claims Data, 2007 to 2024. Clinical Therapeutics. 2026. https://doi.org/10.1016/j.clinthera.2026.06.025
  10. 10. Congenital Cytomegalovirus Among Newborns in Neonatal Intensive Care Units, United States, 2010–2020. Birth Defects Research. 2026;118(7):e70092. https://doi.org/10.1002/bdr2.70092
  11. 11. What do postpartum women know about congenital CMV infection in Greece – A national cross-sectional study. European Journal of Obstetrics & Gynecology and Reproductive Biology. 2026;322:115119. https://doi.org/10.1016/j.ejogrb.2026.115119
  12. 12. Cytomegalovirus congenital infection awareness, knowledge, and attitude towards prenatal screening among Jordanian women: a cross-sectional study. BMC Pregnancy and Childbirth. 2026;26(1):942. https://doi.org/10.1186/s12884-026-09507-1
  13. 13. Delayed hearing loss in congenital cytomegalovirus infection: systematic review and meta-analysis. Brazilian Journal of Otorhinolaryngology. 2026;92(5):101864. https://doi.org/10.1016/j.bjorl.2026.101864
  14. 14. The impact of congenital cytomegalovirus infection among families and caregivers: A qualitative analysis of responses to a public consultation on newborn screening in the UK. Journal of Health Services Research & Policy. 2025;31(3):151-160. https://doi.org/10.1177/13558196251382548
  15. 15. Targeted Cytomegalovirus Testing Linked to Newborn Hearing Screening Was Feasible but Had Low Diagnostic Yield. Acta Paediatrica. 2025;115(2):442-449. https://doi.org/10.1111/apa.70354

Claim-to-source matrix

What each source supports

Every sourced claim in the new sections maps to the references that support it, the section where it is used, and the limitation a reader should keep in mind. Original executive guidance carries no sources because it is guidance, not a finding.

Claim-to-source matrix
Claim groupSourcesYearsUsed inLimitation
Missed cases under targeted or clinical detection[4] [5]2026Current evidenceUniversal screening studies in Israel and Slovenia; Slovenian prevalence is a lower bound because only screen-positive newborns had confirmatory testing.
Low recorded prevalence and testing in routine U.S. care[9] [10]2026Current evidenceClaims data for commercially insured infants and NICU records; coding and testing practices limit ascertainment.
Late-onset hearing loss and sequelae[3] [13]2026Current evidenceMeta-analysis of only three studies; Connecticut cohort of 49 cases.
Follow-up after positive screens and treatment uptake[1] [8] [15]2026, 2025Continuum of careSingle state, health system and regional programs with differing definitions of follow-up.
Specimen performance for screening[6] [5]2026AccessSubstantial heterogeneity among dried blood spot studies.
Hybrid and targeted screening implementation[2] [3] [7]2026AccessSingle-system before-and-after and time series designs without randomized comparison.
Awareness, education and attitudes toward screening[11] [12]2026Equity and trustCross-sectional surveys in Greece and Jordan; transfer to U.S. populations uncertain.
Family experience of delayed diagnosis[14]2025Equity and trustSelf-selected public consultation responses, mostly from families of children with long-term disability.
Greg Wahlstrom in his office at The Healthcare Executive

About the author

Greg Wahlstrom

MBAHCM

President and Chief Executive Officer, The Healthcare Executive

©2014 – 2026 The Healthcare Executive. All rights reserved.

Back to the contents

Health Observance Calendar

See next month’s observances before it starts.

One email ahead of each month with the health observances coming up and the executive briefs that go with them.

Sent by The Healthcare Executive. Unsubscribe at any time. See our Privacy Policy.